Literature DB >> 11761024

Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis.

K Holzmann1, M Weis-Klemm, B Klump, C J Hsieh, F Borchard, M Gregor, R Porschen.   

Abstract

BACKGROUND: We evaluate the usefulness of screening for p53 and Ki-ras mutations in comparison with histological and flow cytometric findings.
METHODS: We analyzed 1486 biopsy samples from 769 locations of 83 patients with long-standing ulcerative colitis enrolled in a surveillance program by means of histology, flow cytometry and SSCP analysis. As a control we used 66 biopsy samples of 16 patients with irritable bowel disease.
RESULTS: With respect to all biopsy samples analyzed, DNA aneuploidy was found in 32.5% (27/83) of patients, dysplasia in 22.9% (15/83), p53 in 21.7% (18/83) and Ki-ras mutations in 18.1% (15/83) of patients. None of these markers was found in our control group. In 7 out of 10 patients who displayed dysplastic findings during endoscopic surveillance p53 and / or Ki-ras mutations were present in at least one colonoscopy. Statistically significant associations were observed between dysplasia and DNA aneuploidy (P < 0.001), between dysplasia and p53 mutations (P = 0.05) and between dysplasia and p53 and/or Ki-ras mutations (P = 0.002). No significant associations were found between dysplasia and Ki-ras mutations alone. The results for the SSCP analysis showed a much broader variation than those for the flow cytometric analysis.
CONCLUSIONS: These results show that screening for p53 and Ki-ras mutations can be a useful adjunct in surveillance of patients with long-standing ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761024     DOI: 10.1080/003655201317097191

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

Review 1.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

2.  Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia.

Authors:  Rajan K Bista; Teresa A Brentnall; Mary P Bronner; Christopher J Langmead; Randall E Brand; Yang Liu
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

3.  Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis.

Authors:  S Fujii; K Tominaga; K Kitajima; J Takeda; T Kusaka; M Fujita; K Ichikawa; S Tomita; Y Ohkura; Y Ono; J Imura; T Chiba; T Fujimori
Journal:  Gut       Date:  2005-05-03       Impact factor: 23.059

4.  Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis.

Authors:  Pavel Wohl; Tomas Hucl; Pavel Drastich; David Kamenar; Julius Spicak; Eva Honsova; Eva Sticova; Alena Lodererova; Jan Matous; Martin Hill; Petr Wohl; Milos Kucera
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

5.  Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study.

Authors:  Monique M Gerrits; Min Chen; Myrte Theeuwes; Herman van Dekken; Marjolein Sikkema; Ewout W Steyerberg; Hester F Lingsma; Peter D Siersema; Bing Xia; Johannes G Kusters; C Janneke van der Woude; Ernst J Kuipers
Journal:  Cell Oncol (Dordr)       Date:  2011-02-17       Impact factor: 6.730

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.